

Natural Product Synthesis

International Edition: DOI: 10.1002/anie.201600591
German Edition: DOI: 10.1002/ange.201600591


Total Synthesis of Cryptocaryol A by Enantioselective Iridium-Catalyzed Alcohol C–H Allylation

Felix Perez, Andrew R. Waldeck, and Michael J. Krische*

Abstract: The polyketide natural product cryptocaryol A is prepared in 8 steps via iridium catalyzed enantioselective diol double C–H allylation, which directly generates an acetate-based triketide stereodiad. In 4 previously reported total syntheses, 17–28 steps were required.


Downregulation of the tumor suppressor protein PDCD4 (programmed cell death 4)^[1] has been linked to diverse human cancers, including liver,^[2a] colorectal,^[2b] brain,^[2c] ovarian,^[2d] and gastric carcinomas.^[2e] Conversely, murine epidermal cells resistant to tumor promotion possess elevated levels of PDCD4.^[1a] Hence, PDCD4 has emerged as a target for the development of anticancer drugs.^[3] In 2011, using a high-throughput cell-based reporter assay^[4] to screen extracts of a Papua New Guinea collection of the plant *Cryptocarya* sp. (Lauraceae, NSC number N098347), Gustafson and co-workers identified a new class of small-molecule PDCD4-stabilizers, the amphiphilic type I polyketides cryptocaryols A–H (Figure 1).^[5] In 2013, Mohapatra reported the total synthesis of the purported structure of cryptocaryol A.^[6a] In elegant contemporaneous work, O'Doherty completed total syntheses of cryptocaryols A and B,^[6b] revising their structural assignments and enabling the first structure–activity studies within this compound class.^[7] Recently, two additional total syntheses of cryptocaryol A were reported by Cossy^[6c] and Dias.^[6d]

The interesting biology, recurring 1,3-polyol motif and prior synthetic work associated with cryptocaryol A made it an interesting compound to further benchmark the utility of catalytic C–C couplings developed in our laboratory.^[8] These processes, which directly convert lower alcohols to higher alcohols, merge the characteristics of transfer hydrogenation with carbonyl addition, exploiting the native reducing ability of alcohols to drive generation of transient carbonyl–organo-metal pairs. Unlike synthetic routes involving conventional carbonyl addition chemistry, discrete alcohol-to-carbonyl redox reactions and use of premetalated carbanions are not required. This technology, which includes methods for stereo- and site-selective primary alcohol C–H allylation^[9] and crotylation,^[10] has been used in total syntheses of several iconic type I polyketide natural products.^[8b,11] By evoking strategies beyond those accessible via conventional carbanion



Initial structural assignment

Cryptocaryol A, $R^1 = R^2 = H$, $R^3 = (CH_2)_{14}Me$, $n = 1$
 Cryptocaryol B, $R^1 = H$, $R^2 = Ac$, $R^3 = (CH_2)_{14}Me$, $n = 1$
 Cryptocaryol C, $R^1 = OH$, $R^2 = H$, $R^3 = (CH_2)_{14}Me$, $n = 1$
 Cryptocaryol D, $R^1 = OH$, $R^2 = Ac$, $R^3 = (CH_2)_{14}Me$, $n = 1$
 Cryptocaryol E, $R^1 = OH$, $R^2 = H$, $R^3 = (CH_2)_{14}Me$, $n = 0$
 Cryptocaryol F, $R^1 = OH$, $R^2 = H$, $R^3 = \text{see below}$, $n = 1$
 Cryptocaryol G, $R^1 = OH$, $R^2 = H$, $R^3 = \text{see below}$, $n = 0$
 Cryptocaryol H, $R^1 = OH$, $R^2 = H$, $R^3 = \text{see below}$, $n = -1$
 For cryptocaryols F–H, $R^3 = \frac{1}{2} \left(\text{CH}_2 \right)_x \text{CH} = \text{CH} \left(\text{CH}_2 \right)_y \text{Me}$
 $x + y = 12$



Revised structural assignment

Cryptocaryol A, $R^1 = R^2 = H$, $R^3 = (CH_2)_{14}Me$, $n = 1$
 Cryptocaryol B, $R^1 = H$, $R^2 = Ac$, $R^3 = (CH_2)_{14}Me$, $n = 1$

Total syntheses of cryptocaryol A

Purported structure

Mohapatra 2013, 28 Steps (LLS), 28 Steps (TS), Ref. [6a]

Revised structure

O'Doherty 2013, 23 steps (LLS), 23 steps (TS), Ref. [6b]

Cossy 2015, 20 steps (LLS), 22 steps (TS), Ref. [6c]

Dias 2015, 17 steps (LLS), 17 steps (TS), Ref. [6d]


Figure 1. Initially proposed structures of cryptocaryols A–H, revised structures of cryptocaryols A and B and total syntheses of cryptocaryol A. [a] For graphical summaries of prior total syntheses, see the Supporting Information. LLS = longest linear sequence; TS = total steps.

chemistry, our technology has provided the most concise routes reported in all cases where it has been applied.


In the context of cryptocaryol A, the double allylation of 1,3-propane diol,^[9c] which directly generates a C_2 -symmetric acetate-based triketide stereodiad, was envisioned as a means of constructing the C3–C9 substructure (Scheme 1). This method has proven especially effective in type I polyketide construction, as illustrated in remarkably concise total syntheses of roxaticin,^[11a] bryostatin 7,^[11b] neopeltolide,^[11c] psymberin (irciniastatin A),^[11d] cyanolide A,^[11e] mandelalide,^[11f,g] cryptolatifolone^[11h] and cryptomoscatone E3.^[11i] Another key feature of the proposed route involved concomitant ring-closing metathesis–cross metathesis^[12] to convert the acrylic ester **3** to an α,β -unsaturated aldehyde, the immediate precursor to Fragment A. Stereoselective substrate directed aldol addition–ketone reduction followed by global deprotection unites Fragment A and Fragment B to deliver cryptocaryol A (Scheme 1).

[*] Dr. F. Perez, A. R. Waldeck, Prof. M. J. Krische
 University of Texas at Austin, Department of Chemistry
 105 E 24th St. (A5300), Austin, TX 78712-1167 (USA)
 E-mail: mkrische@mail.utexas.edu

Supporting information for this article can be found under:
<http://dx.doi.org/10.1002/anie.201600591>.



Scheme 1. Retrosynthetic analysis of cyanolide A via direct generation of an acetate-based triketide stereodiad.




Scheme 2. Synthesis of Fragment A. Yields are of material isolated by silica gel chromatography. See Supporting Information for further experimental details.


Our route to Fragment A is as follows (Scheme 2). The previously reported double C–H allylation of 1,3-propanediol provides the C₂-symmetric diol **1**.^[9c] On gram scale, use of (*R*)-BINAP was preferred due to its relatively low cost, although isolated yields were diminished. Selective monoacylation of diol **1** using the method of Taylor was remarkably efficient, delivering the acrylic ester **2** in 97% yield.^[13] Protection of the hydroxyl moiety of acrylate **2** to form TES-ether **3** was required to increase efficiency in the subsequent 2 steps. Treatment of compound **3** with acrolein in the presence of the Hoveyda-Grubbs-II catalyst in toluene solvent provided the desired RCM-CM product, α -pyrone **4**, in 58% yield. The efficiency of the RCM-CM process was improved significantly upon use of F₈-toluene as solvent,^[14] which enabled acquisition of α -pyrone **4** in 82% yield. Under these conditions, but in the absence of the TES-ether, the desired RCM-CM product was formed in only 14% yield. Related metathesis reactions were explored in Pilli's recently reported synthesis of cryptolatifolione.^[11h] Finally, exposure of α -pyrone **4** to Evans' conditions for oxa-conjugate addition delivered Fragment A as a single stereoisomer.^[15] Attempts to purify Fragment A via flash silica gel chromatography resulted in substantial decomposition. Chromatography on florisil gave better results, providing pure Fragment A in 58% yield. However, crude Fragment A (>90% pure by ¹H NMR) could be obtained in 91% yield, which served equally well in subsequent steps compared to

the chromatographically purified material. Notably, in the synthesis of Fragment A, 4 of the required 5 steps are catalytic transformations and all 4 C–C bonds are forged via metal catalysis.

The synthesis of Fragment B begins with the enantioselective C–H allylation of cetyl alcohol using the iridium catalyst assembled in situ from [Ir(cod)Cl]₂, (*R*)-BINAP, allyl acetate and 4-chloro-3-nitrobenzoic acid.^[9] The homoallylic alcohol **5** was obtained in 72% isolated yield and >95% ee, as determined by Mosher ester analysis.^[16] Exposure of alcohol **5** to *p*-methoxybenzyl trichloroacetimidate in the presence of lanthanum triflate delivered the PMB-ether **6** in 97% yield.^[17] Finally, using Sigman's modification of the Wacker oxida-



Scheme 3. Synthesis of Fragment B. Yields are of material isolated by silica gel chromatography. See Supporting Information for further experimental details.



Scheme 4. Union of Fragment A and Fragment B and total synthesis of cryptocaryol A. Yields are of material isolated by silica gel chromatography. See Supporting Information for further experimental details.

tion,^[18] PMB-ether **6** is transformed into the methyl ketone in 71 % isolated yield, completing the synthesis of Fragment B (Scheme 3).

The union of Fragment A and Fragment B takes advantage of substrate-directed boron-mediated aldol addition (Scheme 4). Whereas enolborinate additions to β -alkoxy aldehydes typically do not display high levels of 1,3-asymmetric induction, exceptional 1,5-*anti*-diastereoselectivity is observed in enolborinate additions involving β -alkoxy methyl ketones as nucleophilic partners.^[19] In the event, Fragment B was exposed to dicyclohexylboron chloride in the presence of triethylamine to form the enol borinate,^[20] which upon exposure to Fragment A under cryogenic conditions (-78°C) delivered the aldol product **7** in 64 % yield as a single stereoisomer. As established in the parent methodological studies,^[19] this level of stereocontrol is significantly higher than that reported for stereochemically related aldol additions between corresponding silyl-protected partners.^[21] Hydroxy-directed reduction of the aldol product **7** delivers the diol **8** in 94 % yield with good levels of 1,3-diastereoselectivity (15:1).^[22] Finally, global deprotection of the acetal and PMB ether using triflic acid/1,3-dimethoxybenzene^[23] delivers cryptocaryol A in a total of 8 steps (LLS) from 1,3-propane diol, fewer than half the steps of any prior synthesis.

In summary, despite impressive methodological advances, the vast majority of de novo chemical syntheses remain distant from the Hendricksonian ideal.^[24,25] Using step-count as the most fundamental metric to evaluate strategic efficiency,^[26] it is evident that classical carbanion chemistry, which requires separate treatment of redox and C–C bond construction events, contributes significantly to this inefficiency. As borne out by an expanding body of work,^[8,11] technologies that merge redox and C–C bond construction events streamline chemical synthesis. In the specific context of cryptocaryol A, the chemistry of carbonyl addition and transfer hydrogenation are united in the form of a double enantioselective alcohol C–H allylation, which directly delivers an acetate-based triketide motif that would otherwise require numerous steps to prepare.^[9c] This transformation, applied in combination with recent advances in alkene metathesis (RCM/CM)^[12] and catalytic diol mono-functionalization,^[13] have enabled a total synthesis of cryptocaryol A in fewer than half the steps previously required, and one can

easily envision application of this approach to other members of this compound class. It is our hope the present exposition in chemical synthesis (along with prior demonstrations)^[11] will motivate further developments in the area of redox-economic C–C bond formation.

Acknowledgements

Acknowledgment is made to the Robert A. Welch Foundation (F-0038) and the NIH (RO1-GM093905) for partial support of this research. Dr. Felix Perez is an NIH-IRACDA Postdoctoral Fellow (NIH 1K12GM102745).

Keywords: enantioselective synthesis · iridium · polyketide · total synthesis · transfer hydrogenation

How to cite: *Angew. Chem. Int. Ed.* **2016**, 55, 5049–5052
Angew. Chem. **2016**, 128, 5133–5136

- [1] a) H. S. Yang, A. P. Jansen, R. Nair, K. Shibahara, A. K. Verma, J. L. Cmarik, N. H. Colburn, *Oncogene* **2001**, 20, 669–676; b) H. S. Yang, A. P. Jansen, A. A. Komar, X. Zheng, W. C. Merrick, S. Costes, S. J. Lockett, N. Sonenberg, N. H. Colburn, *Mol. Cell. Biol.* **2003**, 23, 26–37; c) J. H. Leupold, H. S. Yang, N. H. Colburn, I. Asangani, S. Post, H. Allgayer, *Oncogene* **2007**, 26, 4550–4562; d) R. Nieves-Alicea, N. H. Colburn, A. M. Simeone, A. M. Tari, *Breast Cancer Res. Treat.* **2009**, 114, 203–209.
- [2] a) H. Zhang, I. Ozaki, T. Mizuta, H. Hamajima, T. Yasutake, Y. Eguchi, H. Ideguchi, K. Yamamoto, S. Matsushashi, *Oncogene* **2006**, 25, 6101–6112; b) I. A. Asangani, S. A. Rasheed, D. A. Nikolova, J. H. Leupold, N. H. Colburn, S. Post, *Oncogene* **2008**, 27, 2128–2136; c) Y. Chen, W. Liu, T. Chao, Y. Zhang, X. Yan, Y. Gong, B. Qiang, J. Yuan, M. Sun, X. Peng, *Cancer Lett.* **2008**, 272, 197–205; d) X. Wang, Z. Wei, F. Gao, X. Zhang, C. Zhou, F. Zhu, Q. Wang, Q. Gao, C. Ma, W. Sun, B. Kong, L. Zhang, *Anticancer Res.* **2008**, 28, 2991–2996; e) H. Yu, J. Zeng, X. Liang, W. Wang, Y. Zhou, Y. Sun, S. Liu, W. Li, C. Chen, J. Jia, *PLoS One* **2014**, 9, e105306.
- [3] Reviews: a) B. Lankat-Buttgereit, R. Göke, *Biol. Cell* **2003**, 95, 515–519; b) B. Lankat-Buttgereit, R. Goeke, *Curr. Top. Pept. Protein Res.* **2005**, 7, 63–66; c) B. Lankat-Buttgereit, R. Goeke, *Biol. Cell* **2009**, 101, 309–317.

- [4] J. S. Blees, T. Schmid, C. L. Thomas, A. R. Baker, L. Benson, J. R. Evans, E. I. Goncharova, N. H. Colburn, J. B. McMahon, C. J. Henrich, *J. Biomol. Screening* **2010**, *15*, 21–29.
- [5] T. Grkovic, J. S. Blees, N. H. Colburn, T. Schmid, C. L. Thomas, C. J. Henrich, J. B. McMahon, K. R. Gustafson, *J. Nat. Prod.* **2011**, *74*, 1015–1020.
- [6] a) D. S. Reddy, D. K. Mohapatra, *Eur. J. Org. Chem.* **2013**, 1051–1057; b) Y. Wang, G. A. O'Doherty, *J. Am. Chem. Soc.* **2013**, *135*, 9334–9337; c) E. Brun, V. Bellosta, J. Cossy, *J. Org. Chem.* **2015**, *80*, 8668–8676; d) L. C. Dias, P. K. Kuroishi, E. C. de Lucca, Jr., *Org. Biomol. Chem.* **2015**, *13*, 3575–3584.
- [7] M. F. Cuccarese, Y. Wang, P. J. Beuning, G. A. O'Doherty, *ACS Med. Chem. Lett.* **2014**, *5*, 522–526.
- [8] For recent reviews, see: a) J. M. Ketcham, I. Shin, T. P. Montgomery, M. J. Krische, *Angew. Chem. Int. Ed.* **2014**, *53*, 9142–9150; *Angew. Chem.* **2014**, *126*, 9294–9302; b) A.-M. R. Dechert-Schmitt, D. C. Schmitt, X. Gao, T. Itoh, M. J. Krische, *Nat. Prod. Rep.* **2014**, *31*, 504–513.
- [9] Allylation: a) I. S. Kim, M.-Y. Ngai, M. J. Krische, *J. Am. Chem. Soc.* **2008**, *130*, 6340–6341; b) I. S. Kim, M.-Y. Ngai, M. J. Krische, *J. Am. Chem. Soc.* **2008**, *130*, 14891–14899; c) Y. Lu, I. S. Kim, A. Hassan, D. J. Del Valle, M. J. Krische, *Angew. Chem. Int. Ed.* **2009**, *48*, 5018–5021; *Angew. Chem.* **2009**, *121*, 5118–5121; d) A.-M. R. Dechert-Schmitt, D. C. Schmitt, M. J. Krische, *Org. Lett.* **2012**, *14*, 6302–6305; e) A.-M. R. Dechert-Schmitt, D. C. Schmitt, M. J. Krische, *Angew. Chem. Int. Ed.* **2013**, *52*, 3195–3198; *Angew. Chem.* **2013**, *125*, 3277–3280; f) I. Shin, G. Wang, M. J. Krische, *Chem. Eur. J.* **2014**, *20*, 13382–13389.
- [10] Crotylation: a) I. S. Kim, S. B. Han, M. J. Krische, *J. Am. Chem. Soc.* **2009**, *131*, 2514–2520; b) X. Gao, I. A. Townsend, M. J. Krische, *J. Org. Chem.* **2011**, *76*, 2350–2354; c) X. Gao, H. Han, M. J. Krische, *J. Am. Chem. Soc.* **2011**, *133*, 12795–12800; d) J. R. Zbieg, J. Moran, M. J. Krische, *J. Am. Chem. Soc.* **2011**, *133*, 10582–10586; e) J. R. Zbieg, E. Yamaguchi, E. L. McInturff, M. J. Krische, *Science* **2012**, *336*, 324–327; f) E. L. McInturff, E. Yamaguchi, M. J. Krische, *J. Am. Chem. Soc.* **2012**, *134*, 20628–20631.
- [11] For application of iridium catalyzed double asymmetric allylation of 1,3-diols in the total synthesis of polyketide natural products, see: a) Roxaticin: S. B. Han, A. Hassan, I. S. Kim, M. J. Krische, *J. Am. Chem. Soc.* **2010**, *132*, 15559–15561; b) Bryostatins 7: Y. Lu, S. K. Woo, M. J. Krische, *J. Am. Chem. Soc.* **2011**, *133*, 13876–13879; c) Neopeltolide: Z. Yang, B. Zhang, G. Zhao, J. Yang, X. Xie, X. She, *Org. Lett.* **2011**, *13*, 5916–5919; d) Psymberin (Irciniastatin A): Y. Feng, X. Jiang, J. K. De Brabander, *J. Am. Chem. Soc.* **2012**, *134*, 17083–17093; e) Cyanolide A: A. R. Waldeck, M. J. Krische, *Angew. Chem. Int. Ed.* **2013**, *52*, 4470–4473; *Angew. Chem.* **2013**, *125*, 4566–4569; f) Mandelalide (putative structure): J. Willwacher, A. Fürstner, *Angew. Chem. Int. Ed.* **2014**, *53*, 4217–4221; *Angew. Chem.* **2014**, *126*, 4301–4305; g) Mandelalide (revised structure): M. Willwacher, B. Heggen, C. Wirtz, W. Thiel, A. Fürstner, *Chem. Eur. J.* **2015**, *21*, 10416–10430; h) Cryptolatifolione: L. F. T. Novaes, A. M. Sarotti, R. A. Pilli, *RSC Adv.* **2015**, *5*, 53471–53476; i) Cryptomoscatone E3: L. F. T. Novaes, A. M. Sarotti, R. A. Pilli, *J. Org. Chem.* **2015**, *80*, 12027–12037.
- [12] For selected examples of ring-closing metathesis–cross metathesis, see: a) M.-A. Virolleaud, C. Bressy, O. Piva, *Tetrahedron Lett.* **2003**, *44*, 8081–8084; b) K. J. Quinn, A. K. Isaacs, R. A. Arvary, *Org. Lett.* **2004**, *6*, 4143–4145; c) M.-A. Virolleaud, O. Piva, *Tetrahedron Lett.* **2007**, *48*, 1417–1420; d) P. K. M. Venukadasula, R. Chegondi, S. Maitra, P. R. Hanson, *Org. Lett.* **2010**, *12*, 1556–1559; e) F. Cros, B. Pelotier, O. Piva, *Eur. J. Org. Chem.* **2010**, 5063–5070; f) F. Cros, J. Ruiz, B. Pelotier, O. Piva, *Synlett* **2010**, 2621–2624; g) P. K. M. Venukadasula, R. Chegondi, G. M. Suryan, P. R. Hanson, *Org. Lett.* **2012**, *14*, 2634–2637; h) G. Sabitha, K. Shankaraiah, J. S. Yadav, *Eur. J. Org. Chem.* **2013**, 4870–4878.
- [13] D. Lee, C. L. Williamson, L. Chan, M. S. Chan, M. S. Taylor, *J. Am. Chem. Soc.* **2012**, *134*, 8260–8267.
- [14] C. Samojłowicz, M. Bieniek, A. Pazio, A. Makal, K. Woźniak, A. Poater, L. Cavallo, J. Wójcik, K. Zdanowski, K. Grela, *Chem. Eur. J.* **2011**, *17*, 12981–12993.
- [15] P. A. Evans, A. Grisin, M. J. Lawler, *J. Am. Chem. Soc.* **2012**, *134*, 2856–2859.
- [16] J. A. Dale, D. L. Dull, H. S. Mosher, *J. Org. Chem.* **1969**, *34*, 2543–2549.
- [17] A. N. Rai, A. Basu, *Tetrahedron Lett.* **2003**, *44*, 2267–2269.
- [18] a) B. W. Michel, A. M. Camelio, C. N. Cornell, M. S. Sigman, *J. Am. Chem. Soc.* **2009**, *131*, 6076–6077; b) J. R. McCombs, B. W. Michel, M. S. Sigman, *J. Org. Chem.* **2011**, *76*, 3609–3613; c) B. W. Michel, L. D. Steffens, M. S. Sigman, *J. Am. Chem. Soc.* **2011**, *133*, 8317–8325.
- [19] a) I. Paterson, K. R. Gibson, R. M. Oballa, *Tetrahedron Lett.* **1996**, *37*, 8585–8588; b) D. A. Evans, P. J. Coleman, B. Côté, *J. Org. Chem.* **1997**, *62*, 788–789; c) D. A. Evans, B. Côté, P. J. Coleman, B. T. Connell, *J. Am. Chem. Soc.* **2003**, *125*, 10893–10898.
- [20] H. C. Brown, R. K. Dhar, K. Ganesan, B. Singaram, *J. Org. Chem.* **1992**, *57*, 499–504.
- [21] I. Paterson, R. M. Oballa, R. D. Norcross, *Tetrahedron Lett.* **1996**, *37*, 8581–8584.
- [22] a) K. M. Chen, G. E. Hardtmann, K. Prasad, O. Repic, M. J. Shapiro, *Tetrahedron Lett.* **1987**, *28*, 155; b) K.-M. Chen, K. G. Gunderson, G. E. Hardtmann, K. Prasad, O. Repic, M. J. Shapiro, *Chem. Lett.* **1987**, 1923–1926.
- [23] M. E. Jung, P. Koch, *Tetrahedron Lett.* **2011**, *52*, 6051–6054.
- [24] a) J. B. Hendrickson, *J. Am. Chem. Soc.* **1975**, *97*, 5784–5780; b) I. Shin, T. P. Montgomery, M. J. Krische, *Aldrichimica Acta* **2015**, *47*, 15.
- [25] For an excellent discussion of synthetic efficiency from a biosynthetic perspective, see: G. Jürgens, A. Kirschning, D. A. Candito, *Nat. Prod. Rep.* **2015**, *32*, 723–737.
- [26] “Given the fact that every reaction may be optimized... the total number of chemical transformations is the only variable in the determination of strategic efficiency. Obviously, the fewer the total number of reactions steps in a synthetic design, the higher the level of strategic efficiency.” F. Qiu, *Can. J. Chem.* **2008**, *86*, 903–906.

Received: January 19, 2016

Published online: March 11, 2016